John Leonard

Dr. John Leonard, longtime CEO at Intellia Therapeutics, discusses the foundational elements of building a biotech hub, the influence of the AIDS epidemic on his career, the importance of experience and knowledge in scientific research, and Intellia's long-term DNA editing strategy. He also provides updates on the company's clinical pipeline and future plans.

John Leonard, CEO of Intellia Therapeutics, boasts over 30 years in drug research and development. He discusses Intellia's inception and the challenges faced during the launch of genome editing programs. Insights into the ethical concerns surrounding biotechnology are explored, with a focus on gene editing implications. Leonard also reflects on the competitive landscape of the CRISPR sector and emphasizes the importance of making genetic therapies accessible and affordable for patients. His experiences and commitment highlight the evolving landscape of biotech.